More setbacks for Biogen: state's largest hospital system spurns Alzheimer's drug
The state's largest health care provider has declined to administer Biogen Inc.'s new Alzheimer's drug, citing concerns over its safety and efficacy months after a controversial FDA approval.
Mass General Brigham told the Boston Globe on Tuesday that it would not be using the drug, Aduhelm, generically known as aducanumab. The provider joins a growing cadre of health systems and insurers who are spurning the drug; that group also includes insurance provider Point32Health, one of the la rgest health…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Rowan Walrath Source Type: news